阮祥燕;王月姣;
RUAN Xiang-yan;WANG Yue-jiao;Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University;

• 1:首都医科大学附属北京妇产医院内分泌科

摘要(Abstract)：

随着当代女性对绝经认知的不断提高,越来越多的女性开始进行绝经激素治疗(menopausal hormone therapy, MHT),以缓解绝经相关症状,如月经紊乱、潮热、多汗、睡眠障碍、情绪波动、泌尿生殖道萎缩以及骨质疏松等,进而提高生活质量。但在应用MHT的过程中,乳腺癌的发病风险一直是困扰女性的重要问题之一,而MHT与乳腺癌发病风险的争论亦成为妇科内分泌领域的热点问题。本文基于循证医学证据,阐述如何理性看待二者之间的关系。
With the increasing awareness of women about menopause, an increasing number of women are taking menopausal hormone therapy(MHT) to relieve relevant symptoms(such as irregular bleeding, hot flashes, sweating, sleep disorder, etc.), genitourinary tract atrophy, and osteoporosis. But the risk of breast cancer has always been one of the major concerns for women using MHT. The main safety issue in MHT is breast cancer. The conflict between MHT and the risk of breast cancer has been a hot topic in the field of gynecological endocrinology. This article aims to tell us how to rationally view the relationship between the two based on evidence-based medicine.

关键词(KeyWords)： 绝经激素治疗;乳腺癌;绝经;绝经相关症状;雌激素;孕激素
menopausal hormone therapy;breast cancer;menopause;symptoms of menopause;estrogen;progesterone

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81671411);; 北京市自然科学基金(7162062);; 北京市医院管理中心“登峰”计划专项经费(DFL20181401)~~

作者(Authors): 阮祥燕;王月姣;
RUAN Xiang-yan;WANG Yue-jiao;Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University;

参考文献(References)：

• [1] Parker M,Bucknall M,Jagger C,et al.Population-based estimates of healthy working life expectancy in England at age 50 years:analysis of data from the English Longitudinal Study of Ageing[J].Lancet Public Health,2020,5:e395-e403.
• [2] North American Menopause Society.The 2012 hormone therapy position statement of:The North American Menopause Society[J].Menopause,2012,19:257-271.
• [3] 中国老年学和老年医学学会骨质疏松分会妇产科专家委员会与围绝经期骨质疏松防控培训部.围绝经期和绝经后妇女骨质疏松防治专家共识[J].中国临床医生杂志，2020,48:903-908.
• [4] Collaborative Group on Hormonal Factors in Breast Cancer.Type and timing of menopausal hormone therapy and breast cancer risk:individual participant meta-analysis of the worldwide epidemiological evidence[J].Lancet,2019,394:1159-1168.
• [5] Rossouw JE,Anderson GL,Prentice RL,et al.Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results From the Women's Health Initiative randomized controlled trial[J].JAMA,2002,288:321-333.
• [6] McTiernan A,Chlebowski RT,Martin C,et al.Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the Women's Health Initiative randomized trial[J].J Clin Oncol,2009,27:6135-6143.
• [7] Chlebowski RT,Anderson GL,Aragaki AK,et al.Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials[J].JAMA,2020,324:369-380.
• [8] Mello ML,Vidal BC,Russo IH,et al.DNA content and chromatin texture of human breast epithelial cells transformed with 17-beta-estradiol and the estrogen antagonist ICI 182,780 as assessed by image analysis[J].Mutat Res,2007,617:1-7.
• [9] Ruan X,Mueck AO.The choice of progestogen for HRT in menopausal women:breast cancer risk is a major issue[J].Horm Mol Biol Clin Investig,2018,37:1-22.
• [10] Cavalieri E,Chakravarti D,Guttenplan J,et al.Catechol estrogen quinones as initiators of breast and other human cancers:implications for biomarkers of susceptibility and cancer prevention[J].Biochim Biophys Acta,2006,1766:63-78.
• [11] Li X,Ruan X,Gu M,et al.PGRMC1 can trigger estrogen-dependent proliferation of breast cancer cells:estradiol vs.equilin vs.ethinylestradiol[J].Climacteric,2019,22:483-488.
• [12] Fournier A,Berrino F,Riboli E,et al.Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort[J].Int J Cancer,2005,114:448-454.
• [13] Ruan X,Neubauer H,Yang Y,et al.Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells[J].Climacteric,2012,15:467-472.
• [14] Mohammed H,Russell IA,Stark R,et al.Progesterone receptor modulates ERalpha action in breast cancer[J].Nature,2015,523:313-317.
• [15] 纪树峰，吴爱国，杨华峰.黄体酮受体膜成分-1的表达与乳腺癌的恶性表型有关[J].南方医科大学学报，2012,32:635-63.[15] Ji SF,Wu AG,Yang HF.Expression of progesterone receptor membrane component-1 is associated with the malignant phenotypes of breast cancer[J].Nan Fang Yi Ke Da Xue Xue Bao,2012,32:635-638.
• [16] Zhao Y,Ruan X,Wang H,et al.The presence of a membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone:A xenograft model[J].Maturitas,2017,102:26-33.
• [17] Ruan X,Gu M,Cai G,et al.Progestogens and PGRMC1-dependent breast cancer tumor growth:An in-vitro and xenograft study[J].Maturitas,2019,123:1-8.
• [18] Ruan X,Zhang Y,Mueck AO,et al.Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer[J].Menopause,2017,24:203-209.
• [19] 中华医学会妇产科学分会绝经学组.中国绝经管理与绝经激素治疗指南(2018)[J].协和医学杂志，2018,9:512-525.[19] Menopause Group,Obstertrics and Gynecology Branch,Chinese Medical Association.2018 Chinese Guideline on Menopause Management and Menopause Hormone Therapy[J].Xie He Yi Xue Za Zhi,2018,9:512-525.
• [20] 张雪，董晓平，管雅喆，等.女性乳腺癌流行病学趋势及危险因素研究进展[J].肿瘤防治研究，2021,48:87-92.[20] Zhang X,Dong XP,Guan YZ,et al.Research Progress on Epidemiological Trend and Risk Factors of Female Breast Cancer[J].Zhong Liu Fang Zhi Yan Jiu,2021,48:87-92.
• [21] Giordano SH.Breast Cancer in Men[J].N Engl J Med,2018,378:2311-2320.